Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-5125 in Adults With Selected Advanced Solid Tumors
NCT06399757Phase 1Completed
- Sponsor
- Apollo Therapeutics
- Start
- Jun 2024
- Primary completion
- Jul 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APL-5125 in colorectal cancer (CRC), cholangiocarcinoma (CCA), appendiceal adenocarcinoma and 6 more, sponsored by Apollo Therapeutics. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 1 year, Incidence of dose limiting toxicities at 4 weeks and 1 more. Started Jun 2024; status: completed.
02
Drugs
APL-5125
03
Conditions
colorectal cancer (CRC)cholangiocarcinoma (CCA)appendiceal adenocarcinomapancreatic adenocarcinoma (PDAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT06399757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06399757.